Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499308 | 1.00 | GRIN1 (0.59) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL4422661 | 0.99 | GRIN1 (0.58) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL4422653 | 0.99 | GRIN1 (0.58) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8190768 | 0.94 | GRIN1 (0.55) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8190756 | 0.94 | GRIN1 (0.55) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8181079 | 0.93 | GRIN1 (0.54) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8181067 | 0.93 | GRIN1 (0.54) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL1720270 | 0.91 | GRIN1 (0.52) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL30521938 | 0.91 | GRIN1 (0.52) | GRIN1MEN1LMNACYP1A2MAPK1 | |
| SCHEMBL8181069 | 0.85 | MEN1 (0.49) | GRIN1MEN1LMNACYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| EP-2407454-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2012-01-18 | — | — | EP | claimed |
| US-20110319463-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AS ACTIVE INGREDIENTS | Saten Pharamaceuticals Co., Ltd. (JP) | 2011-12-29 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | claimed |
| EP-2220075-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | claimed |
| EP-2220074-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
| EP-0966463-A1 | CRYSTALLINE HYDRATED SODIUM SALT OF (E)-4,6-DICHLORO-3-(2-OXO-1-PHENYLPYRROLIDIN-3-YLIDENE METHYL)-1H-INDOLE-2-CARBOXYLIC ACID | GLAXO WELLCOME S.p.A. (IT) | 1999-12-29 | — | — | EP | claimed |
| US-5962496-A | CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME SPA (IT) | 1999-10-05 | — | — | US | claimed |
| WO-1998039327-A1 | CRYSTALLINE HYDRATED SODIUM SALT OF (E)-4,6-DICHLORO-3-(2-OXO-1-PHENYLPYRROLIDIN-3-YLIDENE METHYL)-1H-INDOLE-2-CARBOXYLIC ACID | GLAXO WELLCOME S.P.A. (IT) | 1998-09-11 | — | — | WO | claimed |
| US-5760059-A | ANTAGONISTS OF EXCITATORY AMINO ACIDS, TREATMENT OF NEURODEGENERATIVE DISEASES | GLAXO WELLCOME SPA (IT) | 1998-06-02 | — | — | US | claimed |
| EP-0723541-A1 | INDOLE DERIVATIVES AS NMDA ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 1996-07-31 | — | — | EP | claimed |
| WO-1995010517-A1 | INDOLE DERIVATIVES AS NMDA ANTAGONISTS | GLAXO WELLCOME S.P.A. (IT) | 1995-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | GRIN1 136/4885MEN1 3810/4885LMNA 3365/4885 |
| US-20110319463-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AS ACTIVE INGREDIENTS | ALDH1A2, NEFM, QDPR | GRIN1 233/4885MEN1 2599/4885LMNA 2446/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | GRIN1 304/4885MEN1 4616/4885LMNA 3266/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | GRIN1 4/4885MEN1 4256/4885LMNA 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.